Routine next generation sequencing of lymphoid malignancies: clinical utility and challenges from a 3-Year practical experience
暂无分享,去创建一个
[1] Ryan D. Morin,et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. , 2020, Cancer cell.
[2] L. Bubendorf,et al. Extensive Emperipolesis of Neoplastic Lymphocytes by Mesothelial Cells in Pleural Effusion Cytology in a Case of a Mediastinal T-Cell Lymphoblastic Lymphoma: A Rare but Diagnostically Useful Phenomenon , 2019, Acta Cytologica.
[3] K. Davies,et al. Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing. , 2019, Journal of Visualized Experiments.
[4] A. Intlekofer,et al. Using genomic data for selecting the treatment of lymphoma patients. , 2019, Current opinion in hematology.
[5] A. Tzankov,et al. T-lymphoblastic lymphoma after previous thymoma: how NGS helps establishing the diagnosis and procures new insights , 2018, Leukemia & lymphoma.
[6] P. Tamayo,et al. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials , 2018, Cancers.
[7] J. Delabie,et al. Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease , 2018, British journal of haematology.
[8] A. Cleton-Jansen,et al. Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing. , 2018, The Journal of molecular diagnostics : JMD.
[9] A. Tzankov,et al. Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines , 2018, Leukemia & lymphoma.
[10] Alexander V Penson,et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. , 2018, Blood.
[11] F. Cavalli,et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. , 2018, Blood.
[12] Stefano Monti,et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.
[13] Roland Schmitz,et al. Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.
[14] A. Tzankov,et al. High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations , 2018, Leukemia.
[15] T. Haferlach,et al. Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing , 2018, Leukemia.
[16] D. Dunson,et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.
[17] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[18] I. Flinn,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[19] J. Hernández-Rivas,et al. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia , 2017, British Journal of Cancer.
[20] Ryan D. Morin,et al. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. , 2017, Blood.
[21] K. Naresh,et al. Mutational landscape of B‐cell post‐transplant lymphoproliferative disorders , 2017, British journal of haematology.
[22] R. Foà,et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. , 2017, Blood.
[23] C. Mamot,et al. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort , 2017, Journal of Hematology & Oncology.
[24] H. Kantarjian,et al. Cancer Drugs: An International Comparison of Postlicensing Price Inflation. , 2017, Journal of oncology practice.
[25] O. Elemento,et al. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. , 2017, Cancer discovery.
[26] J. Delabie,et al. High Frequency of Somatic Mutations of KMT2D and CARD11 Genes in Cold Agglutinin Disease , 2016 .
[27] R. Kirken,et al. Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors. , 2016, Clinical cancer drugs.
[28] R. Yelensky,et al. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. , 2016, Cancer research.
[29] C. Ruiz,et al. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis , 2016, Leukemia.
[30] S. Lippman,et al. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience , 2016, Molecular Cancer Therapeutics.
[31] C. Copie-Bergman,et al. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study , 2016, Clinical Cancer Research.
[32] Ryan D. Morin,et al. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas , 2015, Clinical Cancer Research.
[33] Donavan T. Cheng,et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. , 2015, Drug discovery today.
[34] M. Grever,et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. , 2015, The New England journal of medicine.
[35] L. Staudt,et al. Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling , 2015, The American journal of surgical pathology.
[36] Robert Kridel,et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.
[37] E. V. Van Allen,et al. Next-generation sequencing to guide cancer therapy , 2015, Genome Medicine.
[38] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Massimo Gadina,et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.
[40] N. Leslie,et al. PTEN inhibitors: an evaluation of current compounds. , 2015, Advances in biological regulation.
[41] J. Lee,et al. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. , 2014, Cancer research.
[42] D. Neuberg,et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.
[43] A. Behrens,et al. ATM signalling and cancer , 2014, Oncogene.
[44] A. Marx,et al. Thymoma with loss of keratin expression (and giant cells): a potential diagnostic pitfall , 2014, Virchows Archiv.
[45] S. Lippman,et al. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. , 2014, The oncologist.
[46] H. Goldschmidt,et al. Targeting the BRAF V600E mutation in multiple myeloma. , 2013, Cancer discovery.
[47] R. Kurzrock,et al. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Richard Simon,et al. Implementing personalized cancer genomics in clinical trials , 2013, Nature Reviews Drug Discovery.
[49] R. Spang,et al. SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients , 2012, Oncotarget.
[50] M. Loh,et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2012, Blood.
[51] N. Harris,et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.
[52] K. Flaherty,et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[53] M. Brown,et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.
[54] S. Mustjoki,et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. , 2012, The New England journal of medicine.
[55] C. Bloomfield,et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia , 2012, Leukemia.
[56] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[57] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[58] D. Bar-Sagi,et al. RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.
[59] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[60] S. Pileri,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.
[61] J. Renauld,et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors , 2011, Haematologica.
[62] C. Klemke,et al. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. , 2011, Blood.
[63] Raul Rabadan,et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.
[64] M. Loh,et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.
[65] Lee T. Sam,et al. Transcriptome Sequencing to Detect Gene Fusions in Cancer , 2009, Nature.
[66] M. Muckenthaler,et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. , 2006, Blood.
[67] Andrew P. Weng,et al. Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.